Viralgen and two labs based in the Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard University have partnered to develop and manufacture an innovative approach to gene ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the initiation of Part B of ...

Joon Lee, an analyst from Truist Financial, has initiated a new Buy rating on Solid Biosciences (SLDB).Stay Ahead of the Market:Discover ...

ProBioGen has expanded both protein and virus manufacturing at its Berlin headquarters—including the commissioning of an ...

4D-310 is under development for the treatment of Fabry disease. The drug candidate is administered through intravenous route. The drug candidate is based on vector evolution platform technology that ...

The publication is entitled, “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies ... technology of directed evolution could be applied to ...

1 Amgen R&D Postdoctoral Fellows Program, Amgen Inc, South San Francisco, CA, United States 2 Amgen Research, Amgen Inc., South San Francisco, CA, United States Tolerogenic vaccines represent a ...

Preliminary data from three patients showed that at a dose level of 3E13 vg/kg, TN-201 treatment resulted in readily detectable levels of the vector DNA in heart tissues, alongside evidence of the ...

Observed liver enzyme elevations, a known side effect of AAV-based gene therapies, were managed with corticosteroids. TN-201 demonstrated robust transduction into cardiomyocytes, with measurable ...

a known side effect of AAV-based gene therapies, were managed with corticosteroids. TN-201 demonstrated robust transduction into cardiomyocytes, with measurable transgene RNA expression and a 3% ...